UNI-EN 44:Notification from Ognian Donev in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
|
| UNI - EN REPORT No | 44 | / | 2024 | |||||||
| Date of issue: | 2024-06-14 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Notification from Ognian Donev in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD | |||||||||||
| Official market - legal basis | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Notification from Ognian Donev in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Donev_Sopharma_EN_12062024.pdf Donev_Sopharma_EN_12062024.pdf | Notification from Ognian Donev in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2024-06-14 | Ognian Donev | Executive director | |||
Cena akcji Sopharma AD
Cena akcji Sopharma AD w momencie publikacji komunikatu to 13.0505 PLN. Sprawdź ile kosztuje akcja Sopharma AD aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma AD.
